Steven Weitman

4.3k total citations · 1 hit paper
94 papers, 3.1k citations indexed

About

Steven Weitman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Steven Weitman has authored 94 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 34 papers in Oncology and 18 papers in Genetics. Recurrent topics in Steven Weitman's work include Cancer therapeutics and mechanisms (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Myeloid Leukemia Research (9 papers). Steven Weitman is often cited by papers focused on Cancer therapeutics and mechanisms (15 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Acute Myeloid Leukemia Research (9 papers). Steven Weitman collaborates with scholars based in United States, France and Poland. Steven Weitman's co-authors include Leslie R. Coney, B A Kamen, Richard H. Lark, Daniel W. Fort, Verna Frasca, V R Zurawski, Barton A. Kamen, Debra S. Jennings, Arthur G. Weinberg and Vincent R. Zurawski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Steven Weitman

93 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.

1992 889 citations Steven Weitman, Richard H. Lark et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven Weitman United States	26	1.2k	880	472	356	344	94	3.1k
J Cassidy United Kingdom	33	1.2k 1.0×	1.7k 1.9×	549 1.2×	332 0.9×	833 2.4×	79	4.5k
Henk J. Broxterman Netherlands	26	1.4k 1.2×	1.3k 1.5×	342 0.7×	268 0.8×	219 0.6×	51	2.8k
Christopher R. Chitambar United States	36	1.5k 1.2×	1.3k 1.5×	201 0.4×	386 1.1×	688 2.0×	117	4.5k
Claude Linassier France	28	786 0.6×	738 0.8×	281 0.6×	209 0.6×	348 1.0×	97	2.7k
B A Kamen United States	28	2.1k 1.8×	660 0.8×	550 1.2×	346 1.0×	532 1.5×	57	4.7k
Abraham Abuchowski United States	26	2.0k 1.7×	437 0.5×	949 2.0×	431 1.2×	199 0.6×	44	4.3k
J.B.M. Boezeman Netherlands	31	971 0.8×	456 0.5×	224 0.5×	317 0.9×	1.0k 2.9×	94	3.8k
Manohar Ratnam United States	31	2.8k 2.3×	1.1k 1.3×	813 1.7×	522 1.5×	485 1.4×	103	5.5k
William P. Petros United States	29	1.3k 1.1×	1.2k 1.4×	420 0.9×	629 1.8×	309 0.9×	96	3.7k
John M. Sanders United States	37	1.6k 1.3×	501 0.6×	93 0.2×	265 0.7×	203 0.6×	71	4.0k

Countries citing papers authored by Steven Weitman

Since Specialization

Citations

This map shows the geographic impact of Steven Weitman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Weitman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Weitman more than expected).

Fields of papers citing papers by Steven Weitman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Weitman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Weitman. The network helps show where Steven Weitman may publish in the future.

Co-authorship network of co-authors of Steven Weitman

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Weitman. A scholar is included among the top collaborators of Steven Weitman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Weitman. Steven Weitman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Chen-Pin, Donna M. Lehman, John G. Kuhn, et al.. (2016). Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes. Cancer Prevention Research. 9(10). 779–787. 20 indexed citations

Kelly, Kevin R., Avvaru N. Suhasini, An-Ping Lin, et al.. (2016). Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clinical Cancer Research. 23(5). 1186–1192. 27 indexed citations

Malik, Laeeq, Helen Parsons, Devalingam Mahalingam, et al.. (2014). Predicting success in regulatory approval from Phase I results. Cancer Chemotherapy and Pharmacology. 74(5). 1099–1103. 8 indexed citations

Chen, Chun‐Liang, Devalingam Mahalingam, Paweł A. Osmulski, et al.. (2012). Single‐cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT‐related genes in metastatic prostate cancer. The Prostate. 73(8). 813–826. 178 indexed citations

Feng, Yang, Zhongyu Zhu, Xiaodong Xiao, Steven Weitman, & Dimiter S. Dimitrov. (2007). Depleting soluble ligand (IGF-II) in solid tumor (human breast cancer xenograft) by ligand-specific human monoclonal antibody. Molecular Cancer Therapeutics. 6. 1 indexed citations

Jeha, Sima, Paul S. Gaynon, Bassem I. Razzouk, et al.. (2006). Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 24(12). 1917–1923. 215 indexed citations

Cerna, Cesario Z., et al.. (2003). AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients. Anti-Cancer Drugs. 14(4). 275–280. 5 indexed citations

Hao, Desirée, Jinee Rizzo, Daniel L. Dexter, et al.. (2002). Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642). Investigational New Drugs. 20(3). 261–270. 34 indexed citations

Williams, Jon I., Steven Weitman, Cristina M. González, et al.. (2001). Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.. PubMed. 7(3). 724–33. 56 indexed citations

10.

Weitman, Steven, G. Mangold, Daniel L. Dexter, et al.. (1999). Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemotherapy and Pharmacology. 43(5). 402–408. 16 indexed citations

11.

Hidalgo, Manuel, Elżbieta Izbicka, S. Gail Eckhardt, et al.. (1999). Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Anti-Cancer Drugs. 10(9). 837–844. 20 indexed citations

12.

Diab, Sami, Susan G. Hilsenbeck, Elżbieta Izbicka, Steven Weitman, & Daniel D. Von Hoff. (1999). Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anti-Cancer Drugs. 10(3). 303–307. 8 indexed citations

13.

Petit, Thierry, Elżbieta Izbicka, R. A. Lawrence, et al.. (1999). Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Annals of Oncology. 10(4). 449–453. 21 indexed citations

14.

Britten, Carolyn D., Elżbieta Izbicka, Susan G. Hilsenbeck, et al.. (1999). Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemotherapy and Pharmacology. 44(2). 105–110. 37 indexed citations

15.

DeNapoli, Thomas S., et al.. (1998). Hepatocellular Carcinoma in Children Associated With Gardner Syndrome or Familial Adenomatous Polyposis. Journal of Pediatric Hematology/Oncology. 20(3). 274–274. 44 indexed citations

16.

Casto, Daniel T., Paul J. Thomas, Steven Weitman, et al.. (1998). Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.. Journal of Clinical Oncology. 16(7). 2494–2499. 15 indexed citations

17.

Goren, Marshall P., James C. Griener, Raymond Quigley, et al.. (1997). Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemotherapy and Pharmacology. 41(2). 140–146. 28 indexed citations

18.

Weitman, Steven, et al.. (1996). New drug development for pediatric oncology. Investigational New Drugs. 14(1). 1–10. 6 indexed citations

19.

Fort, Daniel W., Richard H. Lark, Angela K. Smith, et al.. (1993). Accumulation of 5‐methyltetrahydrofolic acid and folylpolyglutamate synthetase expression by mitogen stimulated human lymphocytes. British Journal of Haematology. 84(4). 595–601. 15 indexed citations

20.

Whipple, Julianne K., et al.. (1992). Causes of variability in oral cyclosporine administration. Hospital Pharmacy. 27(9). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact